With the rapid development of biotechnology, antibody engineering has become an important field in modern biomedical research and drug development. Antibody engineering uses recombinant DNA and protein engineering techniques to process, modify, and reassemble antibody genes, thereby preparing antibody molecules with specific functions and properties. However, traditional antibody engineering methods have problems such as long cycles, low efficiency, and high costs, which limit their application in clinical and scientific research. The emergence of Beacon Optofluidic System has brought revolutionary changes to the field of antibody engineering, greatly improving the efficiency of antibody screening, preparation, and optimization.

1、Overview of Beacon Optofluidic System

The Beacon Optofluidic System is a commercial platform launched by Berkeley Lights in 2016. The system combines microfluidic nanoreactor technology (Nano Pen), optoelectronic positioning technology (OEP), and computer systems to achieve integrated sorting, analysis, cultivation, and export of single B cells. This system uses optoelectronic positioning technology to accurately operate individual cells in the nano upgrade chamber of the chip, avoiding damage and interference to cells in traditional methods, thereby improving the accuracy and reliability of experiments.

The core modules of the Beacon system include four steps: import, culture, assay, and export. These four steps are organically combined to smoothly complete all the processes required for single-cell experiments. Automated operation avoids the interference of human factors in the conventional single-cell operation process, and enhances the stability and repeatability of the experiment, making the final results more scientific and reliable.

2、Application of Beacon Optofluidic System in Antibody Engineering

1. Efficient and rapid antibody screening: The Beacon Optofluidic System can screen a large number of single cells in a short period of time, thereby quickly obtaining antibody sequences with specific functions. Traditional antibody screening methods, such as hybridoma technology and phage display technology, have problems such as low screening efficiency, long screening cycles, and loss of antibody diversity. The Beacon system can screen tens of thousands of plasma cells within a day, completing multifunctional analysis of each plasma cell individual (such as binding, blocking, cross reactivity, etc.), thereby quickly obtaining antibody sequences and greatly simplifying and saving downstream recombinant expression validation time and labor costs.

2. Precise and non-destructive single-cell manipulation: The Beacon system utilizes a photoelectric positioning system to accurately and non destructively manipulate thousands of single cells simultaneously, and conduct parallel cultivation, analysis, and other research. This non-destructive operation method ensures that the functions and characteristics of cells are almost unaffected, thereby improving the accuracy and reliability of the experiment. In addition, the Beacon system also supports multiple chip types, flexibly meeting the experimental needs of different fluxes. It can run up to 4 chips and approximately 50000 cells simultaneously, greatly improving the experimental throughput.

3. Automated processes reduce human errors: The entire process of cell introduction, cultivation, cloning, subcloning, detection, screening, etc. in the Beacon system is automated, greatly avoiding possible errors or mistakes caused by manual operations. This automated operation not only improves the efficiency and accuracy of experiments, but also reduces the labor intensity of experimenters, allowing researchers to focus more on experimental design and data analysis.

4. High sensitivity detection: Each NanoPen in the Beacon system has a volume of only 0.5-1 nl, with a single cell placed inside and a density equivalent to 1 E6 cell/ml, making it easy to detect and highly sensitive. Conventional single cells placed in microplates need to be cultured for several weeks to reach a certain density before testing for secreted proteins and other indicators can be performed. The Beacon system can complete these detections in a short period of time, greatly shortening the experimental cycle.

5. Multiple detection and analysis: The Beacon system supports On chip multiple detection, including real-time IgG secretion, multi genus binding, growth rate, cell surface labeling, phenotype screening, activity/death experiments, affinity experiments, multi antigen screening, reporter cell experiments, etc. This multi detection capability enables researchers to conduct multiple experiments on the same platform, thereby gaining a more comprehensive understanding of the function and properties of antibodies.

3、The advantages of Beacon Optofluidic System in antibody engineering

1. Shorten the research and development cycle: The traditional monoclonal antibody preparation process, including selective cultivation, screening of hybridoma positive clones, and monoclonal hybridoma cell production, generally takes 2-3 months. And the Beacon system consolidates all these steps together for processing, reducing the work that originally took several months to complete to 2 days, greatly saving time and accelerating antibody development speed.

2. Improve screening efficiency: The Beacon system can screen a large number of single cells in a short period of time, thereby quickly obtaining antibody sequences with specific functions. This high-throughput screening capability enables researchers to screen a large number of candidate antibodies in a short period of time, improving screening efficiency.

3. Reduce production costs: Traditional antibody production methods have problems such as high production costs and long production cycles. The Beacon system reduces production costs and improves production efficiency through automated operations and efficient screening. In addition, the Beacon system also supports multiple expression modes (such as prokaryotic cells, eukaryotic cells, and plants), which can express antibody molecules in large quantities, further reducing production costs.

4. Improve antibody quality: The Beacon system ensures that the selected antibodies have high quality and specificity through precise and non-destructive single-cell manipulation and multiple detection capabilities. This high-quality antibody has broad application prospects in disease diagnosis, treatment, and scientific research.

The Beacon Optofluidic System, as a revolutionary technology in the field of antibody engineering, provides strong support for antibody screening, preparation, and optimization due to its high efficiency, speed, and precision. With the launch of the Beacon Optofluidic System by Redbert (Beijing) Biotechnology Co., Ltd., it can save you a lot of screening time and greatly reduce production costs. The conventional use of hybridoma or phage display technology usually takes 3-6 months, but the Beacon Optofluidic System device can obtain specific antibody sequences in just 3 days. Single plasma cells can be directly isolated and detected in a 0.5nl system, from which target cells expressing specific antibodies can be screened, and their heavy and light chain mRNAs can be obtained. These mRNAs can be directly used for sequencing and optimization after reverse transcription. In the future, we look forward to the Beacon system continuing to innovate and improve, bringing more surprises and breakthroughs to the field of antibody engineering.

* The above content is collected online for reference only. If the articles on this website involve copyright or other issues, please contact us promptly and we will handle them as soon as possible!